- Mankhwala
- Umboni
- Neuroblastoma
- Chotupa Cholimba
- Umboni
- TILS
- Chithandizo cha Maselo a NK
- Myasthenia Gravis (MG)
- Khansa ya m'magazi ya Lymphoblastic (B-ALL)
- Systemic Lupus Erythematosus (SLE)
- Matenda a khansa ya m'magazi (T-ALL)
- Non Hodgkin Lymphoma (NHL)
- Matenda a Myeloma Yambiri (MM)
- Kufalitsa Lymphom Yaikulu ya B-cell
- B-lymphocytic Leukemia
- Myeloma
Chithandizo cha CAR-T cha Non-Hodgkin Lymphoma (NHL)
Chidule
Non-Hodgkin Lymphoma (NHL) ndi gulu losiyanasiyana la khansa ya m'magazi yochokera mu dongosolo la lymphatic, yokhala ndi mitundu yosiyanasiyana, kuphatikizapo ma B-cell ndi ma T-cell lymphomas. Pakati pa awa, Kufalitsa Large B-Cell Lymphoma (DLBCL) Ndi mtundu wofala kwambiri komanso woopsa wa B-cell NHL. Ngakhale kuti chithandizo cha chemotherapy ndi immunotherapy chapita patsogolo, odwala ambiri omwe ali ndi NHL yobwereranso m'mbuyo kapena yosagwira ntchito amavutika ndi njira zochepa zochizira. Chithandizo cha CAR-T imapereka njira yopambana, yopereka chiyembekezo kwa odwala omwe lymphoma sanayankhe mankhwala achikhalidwe.
Kodi chithandizo cha CAR-T cha NHL n'chiyani?
Chithandizo cha CAR-T (Chimeric Antigen Receptor T-cell) ndi chithandizo champhamvu chomwe chimaphatikizapo kusintha maselo a T a wodwala kuti awonetse cholandirira chomwe chimalimbana ndi maselo a khansa. Kwa NHL, chithandizo cha CAR-T chimayang'ana kwambiri CD19 ndi CD20 Ma antigen pa maselo a B, omwe amapezeka kwambiri pa maselo a malignant lymphoma. Mwa kukulitsa luso la maselo a T kuzindikira ndi kuukira maselo a khansa awa, chithandizo cha CAR-T chimapereka njira yothandiza yothandizira odwala omwe ali ndi lymphoma yobwereranso kapena yokana.
Ubwino Waukulu wa Chithandizo cha CAR-T cha NHL
- Zothandiza pa NHL Yobwerera M'mbuyo ndi YosasinthikaChithandizo cha CAR-T chawonetsa kugwira ntchito bwino kwambiri kwa odwala omwe ali ndi DLBCL ndi mitundu ina ya B-cell NHL omwe sanayankhepo mankhwala osiyanasiyana.
- Kulondola KoyeneraMankhwalawa amalimbana ndi maselo a khansa a B popanda kuvulaza maselo athanzi, zomwe zimachepetsa zotsatira zoyipa zomwe nthawi zambiri zimagwirizanitsidwa ndi mankhwala achikhalidwe.
- Chithandizo Choyenera Kwa Munthu AliyenseChithandizo cha CAR-T chimagwiritsa ntchito maselo a T a wodwalayo, kupereka njira yochiritsira yokonzedwa mwamakonda yomwe imagwirizana ndi vuto la munthuyo.
- Kuthekera kwa Kukhululukidwa Kwa Nthawi YaitaliOdwala ambiri apeza mpumulo wathunthu kapena pang'ono atalandira chithandizo cha CAR-T, ndipo ena apulumuka kwa nthawi yayitali, ngakhale atalandira chithandizo cha chemotherapy kangapo.
Njira Yothandizira
- Kusonkhanitsa maselo a T: Maselo a T amatengedwa kuchokera m'magazi a wodwalayo kudzera mu njira yotchedwa leukapheresis, yofanana ndi kupereka magazi.
- Kupanga maselo a TMu labotale, ma T-cell omwe asonkhanitsidwa amasinthidwa majini kuti azitha kutulutsa ma receptor omwe amalunjika ku ma antigen enaake monga CD19 kapena CD20 amapezeka pa maselo a lymphoma.
- Kulowetsedwa kwa CAR-T: Maselo a T akamakula ndi kusinthidwa, amabwereranso m'magazi a wodwalayo kuti akaukire maselo a lymphoma.
- Kuyang'anira ndi Kubwezeretsa: Pambuyo popatsidwa mankhwala oletsa kutupa, odwala amawunikidwa kuti awone zotsatirapo zake, monga cytokine release syndrome (CRS) ndi neurotoxicity, zomwe zonsezi zimatha kuthandizidwa ndi chithandizo choyenera chamankhwala.
Chifukwa Chiyani Muyenera Kusankha Chithandizo cha BIOOCUS's CAR-T cha NHL?
- Ukadaulo Wamakono wa CAR-TBIOOCUS imagwiritsa ntchito ukadaulo wapamwamba wa CAR-T kuti ipereke chithandizo chapamwamba kwambiri komanso chothandiza kwambiri cha NHL, pogwiritsa ntchito kafukufuku waposachedwa kuti zitsimikizire zotsatira zabwino.
- Gulu la Akatswiri a ZamagaziGulu lathu la akatswiri a matenda a magazi, a khansa, ndi akatswiri a immunotherapy amagwira ntchito limodzi kuti apereke mapulani ochiritsira payekha kwa wodwala aliyense.
- Kupambana Kotsimikizika Pochiza DLBCLBIOOCUS yathandiza odwala ambiri a NHL ndi chithandizo cha CAR-T, zomwe zathandiza kwambiri, kuphatikizapo kuchira kwathunthu ndi kupulumuka kosatha, makamaka kwa odwala omwe ali ndi DLBCL yobwerera m'mbuyo kapena yokana.
- Thandizo Lonse la OdwalaKuyambira pa upangiri woyamba mpaka chithandizo cha pambuyo pa chithandizo, BIOOCUS imapereka chithandizo chokwanira kwa odwala ochokera kumayiko ena, kuonetsetsa kuti ulendo wawo wonse ukuyenda bwino komanso mothandiza panthawi yonse ya chithandizo chawo.
Umboni Wachipatala ndi Mitengo Yopambana
-
Chithandizo cha CAR-T cha NHL, makamaka cha DLBCL, chawonetsa zotsatira zabwino kwambiri m'mayesero azachipatala komanso kugwiritsa ntchito zenizeni. Kwa odwala omwe alandira chithandizo cha mitundu yosiyanasiyana koma osapambana, chithandizo cha CAR-T chakhala njira yopulumutsa moyo.
- Nkhani ya Wodwala: Kufalikira kwa B-Cell Lymphoma Yaikulu (DLBCL)—Kuchira Kodabwitsa Pambuyo pa Chithandizo cha CAR-T
- Kupambana kwa Zachipatala: Chithandizo cha CAR-T cha DLBCL Yobwerera M'mbuyo—Njira Yopezera Chikhululukiro Chokwanira
- DLBCL Yosagonja Mizere Yambiri: Kafukufuku Wokhudza Kugwira Ntchito kwa Chithandizo cha CAR-T mu Advanced Lymphoma
Kafukufukuyu akuwonetsa kuthekera kosintha kwa chithandizo cha CAR-T kwa odwala omwe ali ndi NHL, makamaka omwe ali ndi DLBCL yolimba komanso yosagwira ntchito m'mizere yambiri. Odwala ambiri apeza mpumulo kwa nthawi yayitali ndipo ayambiranso moyo wawo wabwino atalandira chithandizo.
Deta Yachipatala
Zizindikiro za CD19+20CAR-T:Odwala omwe ali ndi B-cell non Hodgkin's lymphoma
| Mtengo wa CR wa mwezi umodzi | Mtengo wa PR wa mwezi umodzi | Mtengo wa OR wa mwezi umodzi | CRS≥3 | CRES≥3 |
| 71.95% (59/82) | 25.6 (21/82) | 97.55(80/82) | 12.19% (10/82) | 0 |
Zizindikiro za CD19+22CAR-T:Chithandizo cha odwala omwe ali ndi vuto la khansa ya m'magazi ya B-lymphocytic omwe abwereranso ku CD19 komanso omwe ali ndi vuto la kuchepa kwa magazi m'thupi
| Mtengo wa CR wa mwezi umodzi | Mtengo wa PR wa mwezi umodzi | Mtengo wa OR wa mwezi umodzi | CRS≥3 | CRES≥3 |
| 92.1% (35/38) | 7.9% (3/38) | 100% (38/38) | 15.79% (6/38) | 0 |
Zizindikiro za BCMACAR-T:Chithandizo cha myeloma yambiri yobwereranso komanso yokana
| Mtengo wa CR wa mwezi umodzi | Mtengo wa PR wa mwezi umodzi | Mtengo wa OR wa mwezi umodzi | CRS≥3 | CRES≥3 |
| 72.41% (21/29) | 27.59% (8/29) | 100% (29/29) | 6.9% (2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.



